Publicacións nas que colabora con Germán Bou Arévalo (8)

2023

  1. Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 5, pp. 1195-1200

2022

  1. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 10, pp. 2809-2815

2021

  1. Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections

    The Journal of antimicrobial chemotherapy, Vol. 76, Núm. 1, pp. 91-100

  2. Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis

    Clinical Microbiology and Infection, Vol. 27, Núm. 11, pp. 1631-1637

2020

  1. Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection

    The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 11, pp. 3209-3217

  2. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

    The Lancet, Vol. 396, Núm. 10250, pp. 535-544

2019

  1. Challenging antimicrobial susceptibility and evolution of resistance (oxa-681) during treatment of a long-term nosocomial infection caused by a pseudomonas aeruginosa ST175 Clone

    Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 10

2018

  1. Reporting antimicrobial susceptibilities and resistance phenotypes in Acinetobacter spp: A nationwide proficiency study

    Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 3, pp. 692-697